Form 4: Akamai CTO Sells 3,000 Shares Under 10b5-1 Plan
Insider Transaction Report
Akamai Technologies' Chief Technology Officer, Robert Blumofe, executed a pre-planned sale of 3,000 common shares at a weighted average price of $87.6836.
Summary
- Robert Blumofe, Chief Technology Officer of Akamai Technologies Inc. (AKAM), reported a sale of 3,000 shares of common stock.
- The transaction occurred on November 14, 2025, at a weighted average price of $87.6836 per share.
- The shares were sold in multiple transactions with prices ranging from $87.24 to $88.23.
- This sale was conducted pursuant to a Rule 10b5-1 Plan adopted by Dr. Blumofe on March 12, 2025.
- Following the transaction, Dr. Blumofe directly beneficially owns 21,410 shares of common stock.
- Additionally, Dr. Blumofe indirectly beneficially owns 64.184 shares through a 401(k) Plan as of November 13, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan indicates a pre-scheduled, non-discretionary transaction, mitigating concerns about opportunistic selling based on new information.
Positives
- The sale was executed under a Rule 10b5-1 Plan, which indicates a pre-scheduled transaction not based on new material non-public information, enhancing transparency and reducing concerns about opportunistic insider trading.
Negatives
- An insider sale, even if pre-planned, can sometimes be interpreted by investors as a signal, potentially leading to negative sentiment or a perception of diversification away from the company's stock.
Risks
- Potential for negative investor sentiment or misinterpretation of the insider sale, despite it being pre-planned under a 10b5-1 plan.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This insider transaction report is specific to Akamai Technologies and does not provide broader industry trends or competitive analysis. It reflects an individual executive's pre-planned stock diversification.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Adoption | The sale was made pursuant to a Rule 10b5-1 Plan adopted by Dr. Blumofe on March 12, 2025, which is a common corporate governance practice for insiders to sell shares in a pre-arranged manner. | 03/12/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations by demonstrating that the transaction was not based on material non-public information. |
Stakeholder Impact
- Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan provides context that it is a pre-planned diversification rather than a reaction to new company-specific news.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date Rule 10b5-1 Plan was adopted by Dr. Blumofe. |
| 11/13/2025 | Date for which indirect beneficial ownership via 401(k) Plan is reported. |
| 11/14/2025 | Date of the reported transaction (sale of common stock). |
Keywords
Akamai Technologies, AKAM, Insider Transaction, Form 4, Stock Sale, Robert Blumofe, Chief Technology Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.